Alzheimer's Disease Clinical Research
As of June 2012 there were more than 330 clinical trials under way to understand and treat Alzheimer's disease. 30 of these studies were human phase three trials, the last step before U.S. Food and Drug Administration approval and marketing.
There are different approaches. One approach is to reduce Amyloid beta, for example with bapineuzumab, an antibody in phase III studies for patients in mild to moderate stage; semagacestat, a γ-secretase inhibitor, MPC-7869; and acc-001 or CAD106, vaccines against amyloid beta. Other approaches are neuroprotective agents, like AL-108 (phase II completed); or metal-protein interaction attenuation, as is the case of PBT2 (phase II completed). Yet another approach is to use general cognitive enhances, as may be the case for memantine, a pharmaceutical approved in the United States and European Union to treat moderate-to-sever AD. Finally, there are basic investigations on the origin and mechanisms of Alzheimer's disease.
Read more about Alzheimer's Disease Clinical Research: Treatments in Clinical Development, Table of Advanced Disease-modifying Drug (DMD) Candidates
Famous quotes containing the words disease and/or research:
“Man is an exception, whatever else he is. If he is not the image of God, then he is a disease of the dust. If it is not true that a divine being fell, then we can only say that one of the animals went entirely off its head.”
—Gilbert Keith Chesterton (1874–1936)
“To be sure, nothing is more important to the integrity of the universities ... than a rigorously enforced divorce from war- oriented research and all connected enterprises.”
—Hannah Arendt (1906–1975)